Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The Glycogen Synthase Kinase-3β Inhibitor LSN 2105786 Promotes Zebrafish Fin Regeneration.

Sarmah S, Curtis C, Mahin J, Farrell M, Engler TA, Sanchez-Felix MV, Sato M, Ma YL, Chu S, Marrs JA.

Biomedicines. 2019 Apr 19;7(2). pii: E30. doi: 10.3390/biomedicines7020030.

2.

Parasitoid biology preserved in mineralized fossils.

van de Kamp T, Schwermann AH, Dos Santos Rolo T, Lösel PD, Engler T, Etter W, Faragó T, Göttlicher J, Heuveline V, Kopmann A, Mähler B, Mörs T, Odar J, Rust J, Tan Jerome N, Vogelgesang M, Baumbach T, Krogmann L.

Nat Commun. 2018 Aug 28;9(1):3325. doi: 10.1038/s41467-018-05654-y.

3.

Sprint to work: A novel model for team science collaboration in academic medicine.

Sinha SS, Engler TA, Nallamothu BK, Ibrahim AM, Verhey-Henke A, Kerppola M, Ellimoottil C, Ryan AM.

Perspect Med Educ. 2018 Aug;7(4):281-285. doi: 10.1007/s40037-018-0442-9.

4.

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.

Wijeratne A, Xiao J, Reutter C, Furness KW, Leon R, Zia-Ebrahimi M, Cavitt RN, Strelow JM, Van Horn RD, Peng SB, Barda DA, Engler TA, Chalmers MJ.

ACS Med Chem Lett. 2018 May 21;9(6):557-562. doi: 10.1021/acsmedchemlett.8b00110. eCollection 2018 Jun 14.

5.

Ovarian cyst removal influences ovarian reserve dependent on histology, size and type of operation.

Henes M, Engler T, Taran FA, Brucker S, Rall K, Janz B, Lawrenz B.

Womens Health (Lond). 2018 Jan-Dec;14:1745506518778992. doi: 10.1177/1745506518778992.

6.

The cryo-electron microscopy structure of huntingtin.

Guo Q, Bin Huang, Cheng J, Seefelder M, Engler T, Pfeifer G, Oeckl P, Otto M, Moser F, Maurer M, Pautsch A, Baumeister W, Fernández-Busnadiego R, Kochanek S.

Nature. 2018 Mar 1;555(7694):117-120. doi: 10.1038/nature25502. Epub 2018 Feb 21.

7.

The immunopeptidomic landscape of ovarian carcinomas.

Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1.

8.

Heart rate variability during treatment of breakthrough pain in patients with advanced cancer: a pilot study.

Masel EK, Huber P, Engler T, Watzke HH.

J Pain Res. 2016 Dec 12;9:1215-1220. doi: 10.2147/JPR.S120343. eCollection 2016.

9.

Factors Associated With Intestinal Constipation in Chronic Patients With Stroke Sequelae Undergoing Rehabilitation.

Engler TM, Aguiar MH, Furtado ÍA, Ribeiro SP, de Oliveira P, Mello PA, Padula MP, Beraldo PS.

Gastroenterol Nurs. 2016 Nov/Dec;39(6):432-442.

PMID:
27922514
10.

Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.

Krutzke L, Prill JM, Engler T, Schmidt CQ, Xu Z, Byrnes AP, Simmet T, Kreppel F.

J Control Release. 2016 Aug 10;235:379-392. doi: 10.1016/j.jconrel.2016.06.022. Epub 2016 Jun 11.

11.

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.

Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M.

PLoS One. 2015 Apr 27;10(4):e0125028. doi: 10.1371/journal.pone.0125028. eCollection 2015.

12.

Stroke: bowel dysfunction in patients admitted for rehabilitation.

Engler TM, Dourado CC, Amâncio TG, Farage L, de Mello PA, Padula MP.

Open Nurs J. 2014 Nov 19;8:43-7. doi: 10.2174/1874434601408010043. eCollection 2014.

13.

Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo.

Prill JM, Subr V, Pasquarelli N, Engler T, Hoffmeister A, Kochanek S, Ulbrich K, Kreppel F.

PLoS One. 2014 Jan 27;9(1):e82716. doi: 10.1371/journal.pone.0082716. eCollection 2014.

14.

Microstructured optical fibers and live cells: a water-soluble, photochromic zinc sensor.

Heng S, McDevitt CA, Stubing DB, Whittall JJ, Thompson JG, Engler TK, Abell AD, Monro TM.

Biomacromolecules. 2013 Oct 14;14(10):3376-9. doi: 10.1021/bm401040v. Epub 2013 Sep 13.

PMID:
23980997
15.

Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro.

Laakkonen JP, Engler T, Romero IA, Weksler B, Couraud PO, Kreppel F, Kochanek S.

PLoS One. 2012;7(9):e45977. doi: 10.1371/journal.pone.0045977. Epub 2012 Sep 27.

16.

High-capacity adenoviral vectors circumvent the limitations of ΔE1 and ΔE1/ΔE3 adenovirus vectors to induce multispecific transgene product-directed CD8 T-cell responses.

Kron MW, Engler T, Schmidt E, Schirmbeck R, Kochanek S, Kreppel F.

J Gene Med. 2011 Dec;13(12):648-57. doi: 10.1002/jgm.1629.

PMID:
22095925
17.

ΔE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum.

Zong S, Kron MW, Epp C, Engler T, Bujard H, Kochanek S, Kreppel F.

J Gene Med. 2011 Dec;13(12):670-9. doi: 10.1002/jgm.1627.

PMID:
22095915
18.

miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Kron MW, Espenlaub S, Engler T, Schirmbeck R, Kochanek S, Kreppel F.

Mol Ther. 2011 Aug;19(8):1547-57. doi: 10.1038/mt.2011.83. Epub 2011 May 10.

19.

A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators.

Sutherland JJ, Low J, Blosser W, Dowless M, Engler TA, Stancato LF.

Mol Cancer Ther. 2011 Feb;10(2):242-54. doi: 10.1158/1535-7163.MCT-10-0720. Epub 2011 Jan 7.

20.

Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.

Prill JM, Espenlaub S, Samen U, Engler T, Schmidt E, Vetrini F, Rosewell A, Grove N, Palmer D, Ng P, Kochanek S, Kreppel F.

Mol Ther. 2011 Jan;19(1):83-92. doi: 10.1038/mt.2010.229. Epub 2010 Oct 19.

21.

Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications.

Espenlaub S, Corjon S, Engler T, Fella C, Ogris M, Wagner E, Kochanek S, Kreppel F.

Hum Gene Ther. 2010 Sep;21(9):1155-67. doi: 10.1089/hum.2009.171.

PMID:
20384482
22.

Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.

Espenlaub S, Wortmann A, Engler T, Corjon S, Kochanek S, Kreppel F.

J Gene Med. 2008 Dec;10(12):1303-14. doi: 10.1002/jgm.1262.

PMID:
18837065
23.

Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere.

Corjon S, Wortmann A, Engler T, van Rooijen N, Kochanek S, Kreppel F.

Mol Ther. 2008 Nov;16(11):1813-24. doi: 10.1038/mt.2008.174. Epub 2008 Aug 19.

24.

Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.

Wortmann A, Vöhringer S, Engler T, Corjon S, Schirmbeck R, Reimann J, Kochanek S, Kreppel F.

Mol Ther. 2008 Jan;16(1):154-62. Epub 2007 Sep 11.

25.

Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.

Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N'cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE.

J Cell Biochem. 2007 Dec 15;102(6):1504-18.

PMID:
17520664
26.

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL.

J Bone Miner Res. 2006 Jun;21(6):910-20.

27.

[Empowering older adults who are organized to search for a new social contract: experiences of the Inter-American Development Bank and Red Tiempos].

Engler T.

Rev Panam Salud Publica. 2005 May-Jun;17(5-6):438-43. Spanish. No abstract available.

PMID:
16053654
28.

The development of potent and selective bisarylmaleimide GSK3 inhibitors.

Engler TA, Malhotra S, Burkholder TP, Henry JR, Mendel D, Porter WJ, Furness K, Diefenbacher C, Marquart A, Reel JK, Li Y, Clayton J, Cunningham B, McLean J, O'toole JC, Brozinick J, Hawkins E, Misener E, Briere D, Brier RA, Wagner JR, Campbell RM, Anderson BD, Vaughn R, Bennett DB, Meier TI, Cook JA.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):899-903.

PMID:
15686883
29.

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E, Iversen PW, Li Y, Lindstrom TD, Marquart AL, McLean J, Mendel D, Misener E, Briere D, O'Toole JC, Porter WJ, Queener S, Reel JK, Owens RA, Brier RA, Eessalu TE, Wagner JR, Campbell RM, Vaughn R.

J Med Chem. 2004 Jul 29;47(16):3934-7.

PMID:
15267232
30.

Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.

Zhu G, Conner SE, Zhou X, Chan HK, Shih C, Engler TA, Al-Awar RS, Brooks HB, Watkins SA, Spencer CD, Schultz RM, Dempsey JA, Considine EL, Patel BR, Ogg CA, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3057-61.

PMID:
15149644
31.

Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.

Faul MM, Engler TA, Sullivan KA, Grutsch JL, Clayton MT, Martinelli MJ, Pawlak JM, LeTourneau M, Coffey DS, Pedersen SW, Kolis SP, Furness K, Malhotra S, Al-awar RS, Ray JE.

J Org Chem. 2004 Apr 30;69(9):2967-75.

PMID:
15104433
32.

Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Engler TA, Furness K, Malhotra S, Sanchez-Martinez C, Shih C, Xie W, Zhu G, Zhou X, Conner S, Faul MM, Sullivan KA, Kolis SP, Brooks HB, Patel B, Schultz RM, DeHahn TB, Kirmani K, Spencer CD, Watkins SA, Considine EL, Dempsey JA, Ogg CA, Stamm NB, Anderson BD, Campbell RM, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2261-7.

PMID:
12824014
33.
34.

Tandem 5 + 2/3 + 2 and 5 + 2/3 + 3 Cycloaddition Reactions.

Engler TA, Scheibe CM, Iyengar R.

J Org Chem. 1997 Nov 28;62(24):8274-8275. No abstract available.

PMID:
11671954
36.

Unexpected beneficial effects of measles immunisation. Who brought measles?

Engler T.

BMJ. 2000 Apr 1;320(7239):939; author reply 939-40. No abstract available.

PMID:
10787260
37.

[Estimating the elastic anisotropy of bone by V(z) measurements].

Hein HJ, Engler T.

Biomed Tech (Berl). 1997;42 Suppl:87-8. German. No abstract available.

PMID:
9517059
38.
39.

[Crisis and health: challenges for the decade of the 90's].

Márquez PV, Engler T.

Educ Med Salud. 1990 Jan-Feb;24(1):7-26. Spanish. No abstract available.

PMID:
2340814
40.

[The general practitioner and community medical services].

Engler T.

Educ Med Salud. 1981;15(2):115-23. Spanish.

PMID:
7274144

Supplemental Content

Loading ...
Support Center